Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 7, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2016-11-09
DOI
10.3389/fphar.2016.00428
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC).
- (2017) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib.
- (2017) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted and exome sequencing identified somatic mutations in hepatocellular carcinoma
- (2016) Yosuke Hirotsu et al. HEPATOLOGY RESEARCH
- Cancer-associated fibroblasts in hepatocellular carcinoma
- (2016) Norio Kubo et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated α-fetoprotein (AFP) from the randomized phase III REACH study.
- (2015) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer
- (2015) Gerald S. Falchook et al. Oncotarget
- Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma
- (2015) Roberta Schmieder et al. NEOPLASIA
- A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
- (2014) Subhajit Roy et al. Anti-Cancer Agents in Medicinal Chemistry
- A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma
- (2014) H. Y. Lim et al. CLINICAL CANCER RESEARCH
- Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET
- (2014) Q. Xiang et al. CLINICAL CANCER RESEARCH
- Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
- (2014) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Hepatocellular carcinoma: clinical frontiers and perspectives
- (2014) Jordi Bruix et al. GUT
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- (2014) Andrew X. Zhu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity
- (2014) Wei-Tien Tai et al. JOURNAL OF HEPATOLOGY
- Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
- (2014) Bradley J Monk et al. LANCET ONCOLOGY
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Time to evolve trial design after everolimus failure
- (2014) Josep M. Llovet Nature Reviews Clinical Oncology
- Early Hepatocellular Carcinoma on the Procrustean Bed of Ablation, Resection, and Transplantation
- (2014) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment
- (2014) Mi Na Kim et al. Expert Review of Gastroenterology & Hepatology
- Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients
- (2013) Y. Zhao et al. ANNALS OF ONCOLOGY
- Hepatocellular Carcinoma: Beyond the Boundaries of Age
- (2013) Fabrizio Benedetto et al. Anti-Cancer Agents in Medicinal Chemistry
- Colorectal Cancer in Elderly Patients: From Best Supportive Care to Cure
- (2013) Massimiliano Berretta et al. Anti-Cancer Agents in Medicinal Chemistry
- A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer
- (2013) A. X. Zhu et al. CLINICAL CANCER RESEARCH
- Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
- (2013) A. X. Zhu et al. CLINICAL CANCER RESEARCH
- Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study
- (2013) Jordi Bruix et al. EUROPEAN JOURNAL OF CANCER
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
- (2013) Josep M. Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: A propensity score matching study
- (2013) Wei Bai et al. Journal of Digestive Diseases
- Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma
- (2013) Richard S. Finn et al. JOURNAL OF HEPATOLOGY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Multicenter Italian Experience in Liver Transplantation for Hepatocellular Carcinoma in HIV-Infected Patients
- (2013) F. Di Benedetto et al. ONCOLOGIST
- Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial
- (2013) Benjamin M. Ellingson et al. RADIOLOGY
- Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma
- (2012) Manon Buijs et al. CANCER
- Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma
- (2012) Han Chong Toh et al. CANCER
- Molecular mechanisms of sorafenib action in liver cancer cells
- (2012) Melchiorre Cervello et al. CELL CYCLE
- Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2012) R. S. Finn et al. CLINICAL CANCER RESEARCH
- Anti-VEGF Strategies – from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer
- (2012) Grzegorz Korpanty et al. CURRENT PHARMACEUTICAL DESIGN
- Regorafenib for cancer
- (2012) Dirk Strumberg et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
- (2012) Armando Santoro et al. LANCET ONCOLOGY
- Efficacy, Safety, and Biomarkers of Single-Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2012) V. Boige et al. ONCOLOGIST
- Cediranib (AZD2171) in Patients With Advanced Hepatocellular Carcinoma
- (2011) Steven Robert Alberts et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Signal transduction by vascular endothelial growth factor receptors
- (2011) Sina Koch et al. BIOCHEMICAL JOURNAL
- Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma
- (2011) Weijing Sun et al. CANCER
- Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2011) J.-W. Park et al. CLINICAL CANCER RESEARCH
- Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma
- (2011) Timothy M. Pawlik et al. JOURNAL OF CLINICAL ONCOLOGY
- Vascular Endothelial Growth Factor Receptor-1 Activation Mediates Epithelial to Mesenchymal Transition in Hepatocellular Carcinoma Cells
- (2011) Zeng Yong Yi et al. JOURNAL OF INVESTIGATIVE SURGERY
- Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus m-TOR inhibitors monotherapy?
- (2011) Fabrizio Di Benedetto et al. JOURNAL OF SURGICAL ONCOLOGY
- Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma
- (2011) A.-C. Piguet et al. MOLECULAR CANCER THERAPEUTICS
- HCC and angiogenesis: possible targets and future directions
- (2011) Andrew X. Zhu et al. Nature Reviews Clinical Oncology
- Hepatocellular Carcinoma in HIV-Infected Patients: Check Early, Treat Hard
- (2011) M. Berretta et al. ONCOLOGIST
- Sorafenib before liver transplantation for hepatocellular carcinoma: risk or give up
- (2011) Fabrizio Di Benedetto et al. TRANSPLANT INTERNATIONAL
- Tyrosine Kinase Inhibitor PTK/ZK Enhances the Antitumor Effects of Interferon-α/5-Fluorouracil Therapy for Hepatocellular Carcinoma Cells
- (2010) Masahiro Murakami et al. ANNALS OF SURGICAL ONCOLOGY
- Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
- (2010) C-H Hsu et al. BRITISH JOURNAL OF CANCER
- Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma
- (2010) Thomas Yau et al. CANCER
- Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In Vivo
- (2010) Kanae Kudo et al. CLINICAL CANCER RESEARCH
- Single-Center Phase II Trial of Transarterial Chemoembolization With Drug-Eluting Beads for Patients With Unresectable Hepatocellular Carcinoma
- (2009) Diane K. Reyes et al. CANCER JOURNAL
- RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer
- (2009) C. Iverson et al. CANCER RESEARCH
- Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study
- (2009) Johannes Lammer et al. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
- Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma
- (2009) Melanie B. Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
- Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
- (2008) H. Huynh et al. CLINICAL CANCER RESEARCH
- Discovery of Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215)
- (2008) Zhen-wei Cai et al. JOURNAL OF MEDICINAL CHEMISTRY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatocellular carcinoma in HIV patients treated by liver transplantation
- (2007) F. Di Benedetto et al. EJSO
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started